Elutia Inc. (NASDAQ:ELUT - Get Free Report) Director Guido Neels bought 15,000 shares of Elutia stock in a transaction on Wednesday, January 28th. The stock was acquired at an average price of $1.06 per share, for a total transaction of $15,900.00. Following the purchase, the director owned 83,750 shares of the company's stock, valued at approximately $88,775. This trade represents a 21.82% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Elutia Stock Performance
Shares of NASDAQ ELUT opened at $1.05 on Friday. The stock has a 50 day moving average price of $0.71 and a 200 day moving average price of $1.18. The firm has a market capitalization of $44.84 million, a price-to-earnings ratio of -1.14 and a beta of 0.62. Elutia Inc. has a 52-week low of $0.50 and a 52-week high of $3.46.
Elutia (NASDAQ:ELUT - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.15. The business had revenue of $3.32 million for the quarter, compared to analysts' expectations of $6.65 million. Analysts forecast that Elutia Inc. will post -1.74 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on ELUT shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of Elutia in a research note on Wednesday, January 21st. Wall Street Zen raised Elutia to a "sell" rating in a research report on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $7.00.
Check Out Our Latest Stock Report on ELUT
Hedge Funds Weigh In On Elutia
Institutional investors and hedge funds have recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new stake in shares of Elutia in the fourth quarter worth about $25,000. Virtu Financial LLC acquired a new position in Elutia in the third quarter valued at approximately $26,000. XTX Topco Ltd purchased a new stake in Elutia in the 2nd quarter worth approximately $28,000. Jane Street Group LLC acquired a new stake in shares of Elutia during the 1st quarter worth approximately $48,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Elutia during the 3rd quarter worth approximately $50,000. Institutional investors and hedge funds own 74.03% of the company's stock.
About Elutia
(
Get Free Report)
Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.
The company's lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
